Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RNAZ Stock Chart & Stats
$7.53
-$0.12(-3.32%)
At close: 4:00 PM EST
$7.53
-$0.12(-3.32%)
Day’s Range― - ―
52-Week Range$6.14 - $468.44
Previous CloseN/A
Volume52.57K
Average Volume (3M)282.59K
Market Cap
$6.81M
Enterprise Value-$2.30M
Total Cash (Recent Filing)$2.84B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.61
Shares Outstanding916,968
10 Day Avg. Volume825,542
30 Day Avg. Volume282,592
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-11.66
Price to Sales (P/S)0.00
P/FCF Ratio-1.76
Enterprise Value/Market Cap-0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit33.21
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Financial RisksRisks include, but are not limited to: safety signals emerge with any of the company’s clinical or preclinical programs.
Operating ExpensesIn 4Q24, the company reported operating expenses of $5.1M, which was significantly higher than 3Q24, likely associated with costs related to dose escalation in the Phase 1 trial of TTX-MC138 for treatment of solid tumors.
TransCode Therapeutics News
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $6.14 and its highest was $468.44 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $6.81M.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is 273 days ago.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$5.28 earnings per share for the quarter, beating the consensus estimate of -$16.17 by $10.89.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Overvalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 916,968 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$5.28 in its last earnings report, beating expectations of -$16.17. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.20% Mutual Funds
1.28% Other Institutional Investors
96.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---